Heron Therapeutics (HRTX) 16.90 $HRTX Heron Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Heron Therapeutics (HRTX) 16.90 $HRTX

Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain
BusinessWire - Mon Aug 01, 5:00AM CDT
---Increase in time to first opioid rescue and decrease in overall opioid use in both studies
HRTX: 16.90 (+0.28)

Heron Therapeutics Announces Appointment of Christian Waage to Board of Directors
BusinessWire - Wed Jun 22, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced the appointment of Christian Waage to Heron's Board of Directors.
HRTX: 16.90 (+0.28)

What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 16.90 (+0.28), TXMD: 7.77 (unch), RMTI: 7.78 (-0.27), SNY: 42.49 (-0.14)

Heron Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 3:51PM CDT
REDWOOD CITY, Calif. (AP) _ Heron Therapeutics Inc. (HRTX) on Thursday reported a loss of $33.4 million in its first quarter.
HRTX: 16.90 (+0.28)

Heron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress
BusinessWire - Thu May 05, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicine that address major unmet medical needs, today reported first quarter 2016 financial results and highlighted recent corporate progress.
HRTX: 16.90 (+0.28)

This Was the Best Performing Healthcare ETF Last Week
Brian Feroldi, The Motley Fool - Motley Fool - Sat Apr 23, 2:17PM CDT
Source: TBIT ON PIXABAY. It was a terrific week to have money invested in the healthcare sector, as the majority of the largest exchange-traded funds that focus on the space smashed the returns of the S&P 500 .  Several of these ETFs gained...
HRTX: 16.90 (+0.28), PJP: 68.37 (+0.63)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (unch), SGYP: 4.13 (+0.05), HRTX: 16.90 (+0.28), RPRX: 2.06 (-0.06)

Is Heron Therapeutics' Stock Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Tue Apr 19, 8:24AM CDT
Image source: Pixabay.  What : Shares of Heron Therapeutics gained over 18% in pre-market trading today on heavy volume after the company announced that there are no remaining substantive deficiencies in the New Drug Application for Sustol, and...
HRTX: 16.90 (+0.28)

Heron Therapeutics Provides Update on FDA Review of SUSTOL(R) NDA
BusinessWire - Mon Apr 18, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), announced today that the U.S. Food and Drug Administration (FDA) has provided the Company with an update on its review of the New Drug Application (NDA) for SUSTOL(R) (granisetron) Injection, extended release. The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.
HRTX: 16.90 (+0.28)

Addiction Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/m28s26/addiction) has announced the addition of the "Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Addiction Overview - Therapeutics Development - Pipeline Products for Addiction - Overview - Pipeline Products for Addiction - Comparative Analysis - Addiction - Therapeutics under Development by Companies - Addiction - Therapeutics under Investigation by Universities/Institutes - Addiction - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Addiction - Products under Development by Companies - Addiction - Products under Investigation by Universities/Institutes - Addiction - Companies Involved in Therapeutics Development Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Aelis Farma S.A.S. - Alkermes Plc - Aphios Corporation - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - C4X Discovery Limited - Camurus AB - Embera NeuroTherapeutics, Inc. - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Grunenthal GmbH - H. Lundbeck A/S - Heptares Therapeutics Limited - Heron Therapeutics, Inc. - Immunovaccine, Inc. - Indivior Plc - INSYS Therapeutics, Inc. - InterveXion Therapeutics LLC - Neurocrine Biosciences, Inc. - Omeros Corporation - P2D Bioscience - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/m28s26/addiction
PFE: 37.31 (+0.42), ALKS: 49.56 (-0.34), ZYNE: 9.20 (+0.36), XNPT: 7.07 (+0.05), OMER: 11.80 (+0.04), INSY: 15.91 (+0.26), NBIX: 51.51 (+1.28), TNXP: 2.05 (-0.02), HRTX: 16.90 (+0.28), ABBV: 66.94 (+0.71), ARNA: 1.68 (+0.01)

Why Heron Therapeutics' Stock Sank Today
George Budwell, The Motley Fool - Motley Fool - Mon Feb 08, 11:45AM CST
What : Shares of the biotech company Heron Therapeutics sank by as much as 15.8% today on greater-than-normal volume for the stock. The good news is that this latest downturn wasn't triggered by a negative catalyst; rather, the stock appears to be...
HRTX: 16.90 (+0.28)

Heron Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference
BusinessWire - Thu Feb 04, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 p.m. ET (10:25 a.m. PT) in New York, NY.
HRTX: 16.90 (+0.28)

Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.41 (-0.14), COLL: 11.86 (-0.27), LLY: 83.18 (+0.29), AGN: 254.86 (+1.91), JNJ: 125.40 (+0.17), INSY: 15.91 (+0.26), EGLT: 7.02 (-0.37), ACAD: 37.23 (+0.19), CLCD: 8.63 (-0.07), HRTX: 16.90 (+0.28), AZN: 33.84 (-0.30), ABBV: 66.94 (+0.71), PTIE: 2.69 (-0.01)

Heron Therapeutics elects Kimberly J. Manhard as EVP of drug development
M2 - Fri Jan 29, 3:48AM CST
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) revealed on Thursday the addition of Kimberly J. Manhard as executive vice president of its drug development.
HRTX: 16.90 (+0.28)

Heron Therapeutics Appoints Kimberly J. Manhard as Executive Vice President of Drug Development
BusinessWire - Thu Jan 28, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced the appointment of Kimberly J. Manhard as Executive Vice President of Drug Development. Ms. Manhard joins the Company today and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.
HRTX: 16.90 (+0.28)

Heron (HRTX) Down, Sustol Review Period Extended by FDA
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 2:05PM CST
Heron Therapeutics, Inc. (HRTX) announced that that the FDA has not yet completed its review process for the marketing application for Sustol.
HRTX: 16.90 (+0.28), GILD: 80.46 (+0.99), GSK: 45.25 (+0.18), ANIK: 50.64 (+0.72)

7 Stocks to Buy in January
Steve Symington, Evan Niu, CFA, Daniel Miller, Matthew DiLallo, Andrés Cardenal, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Wed Jan 13, 9:32PM CST
After the broader market's painful pullback so early this year, skittish investors might be tempted to run for the hills. But for those willing to resist the urge and maintain their composure, this also means opportunity. To capitalize on that...
NFLX: 94.37 (+3.12), HRTX: 16.90 (+0.28), GILD: 80.46 (+0.99), MRK: 58.66 (unch), CMG: 414.08 (-9.91), EOG: 78.70 (-3.00), WMT: 73.78 (+0.81), ABBV: 66.94 (+0.71), RGR: 69.40 (+1.40), SWHC: 30.36 (+0.91)

5 Biotech Stocks That Doubled in 2015
Arpita Dutt - Zacks Investment Research - Thu Jan 07, 11:17AM CST
Here is a look at 5 biotech stocks that doubled in 2015 despite the volatility in the sector.
HRTX: 16.90 (+0.28), SRPT: 25.91 (+0.63), LGND: 138.53 (+3.65), AMGN: 174.16 (+2.13), RVNC: 13.25 (-0.24), ABBV: 66.94 (+0.71), EXEL: 9.27 (+0.09)

The Top 5 Best Performing Biotech Stocks of 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 02, 6:40AM CST
Source: Flickr user stockmonkeys.com The 2015 return of 12.3% for the NASDAQ Biotechnology Index ETF makes the biotech sector one of the market's best-performing baskets this year, and the returns of the five best biotech stocks in the space were...
HRTX: 16.90 (+0.28), ANAC: 99.06 (-0.14), EGRX: 46.57 (+3.43), PRTA: 56.66 (+1.61), EXEL: 9.27 (+0.09)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 227

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 125

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 22

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 58

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 255

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 99

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 147

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 32

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 200

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 111

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

Surfx Sues ONTOS Over Patent Breach in Plasma Tech

Updated Category News Views 55

Surfx's Legal Gambit: A Staunch Defense of Innovation Surfx Technologies, LLC has taken a bold step by filing a federal lawsuit against ONTOS Equipment Systems, Inc. for allegedly infringing on its patents. It's no walk in the park when your cutting-edge plasma systems are at stake. With busy players in the semiconductor, aerospace, and medical device markets, Surfx isn't...

Continue Reading
GeneDx Faces Securities Fraud Suit Over Fabric Deal

Updated Category News Views 82

Trouble in Paradise: GeneDx's Post-Acquisition Blues Ever get that feeling you’ve been handed a lemon? Well, GeneDx Holdings Corp. (NASDAQ: WGS) seems to be in that very predicament with their acquisition of Fabric Genomics. A deal meant to expand markets now casts a long shadow, and the aftermath is stirring up a securities fraud class action lawsuit. If you dipped...

Continue Reading
Insights on the Growing Aluminum Composite Material Market

Updated Category News Views 191

Understanding the Aluminum Composite Material Market The aluminum composite material (ACM) market is witnessing exciting developments as it is projected to reach USD 10.93 billion by 2034, growing at a CAGR of 6.99%. The demand for aluminum composite materials is increasing due to their lightweight properties, durability, and versatility. These materials are primarily...

Continue Reading
Preeclampsia Diagnostics Market Set for Growth Beyond 2032

Updated Category News Views 158

Overview of Preeclampsia Diagnostics Market The Preeclampsia Diagnostics Market is poised to experience significant growth, driven largely by the increasing prevalence of preeclampsia and enhanced awareness among expectant mothers and healthcare professionals. This growth is fueled by innovative product developments from leading companies within the industry and...

Continue Reading
Inszone Insurance Services Expands with Southerland Acquisition

Updated Category News Views 266

Inszone Insurance Services Expands Its Texas Reach Inszone Insurance Services, a leading provider of commercial, personal, and benefits insurance, is excited to announce its recent acquisition of Southerland and Associates, Inc. This move not only solidifies Inszone's presence in Texas but also enhances its capacity to deliver personalized and diverse insurance solutions...

Continue Reading